Solubilizer for nitrogen-containing compound

A solubilizer using tetraalkylammonium or tetraalkylphosphonium ions and carboxylate ions in ionic liquids addresses low solubility issues, enhancing the concentration and stability of nitrogen-containing compounds for pharmaceutical and cosmetic formulations.

JP2024163412AInactive Publication Date: 2024-11-22TORAY INDUSTRIES INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023078966
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing solubilization methods for nitrogen-containing compounds in pharmaceuticals, quasi-drugs, and cosmetics are limited by low solubility, making it difficult to formulate effective formulations for desired administration routes.

Method used

A solubilizer comprising a tetraalkylammonium or tetraalkylphosphonium ion and a carboxylate ion, particularly in the form of an ionic liquid, which enhances the solubility of nitrogen-containing compounds by interacting with them and allowing transfer to other solvents or bases.

Benefits of technology

The solubilizer achieves high solubility and concentration of nitrogen-containing compounds, enabling their use in pharmaceutical compositions and cosmetics, particularly in external preparations, with improved stability and absorption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163412000001
    Figure 2024163412000001
  • Figure 2024163412000002
    Figure 2024163412000002
  • Figure 2024163412000003
    Figure 2024163412000003
Patent Text Reader

Abstract

To provide a solubilizer that enables high-concentration dissolution of nitrogen-containing compounds for use as an active ingredient in pharmaceuticals, quasi drugs or cosmetic products.SOLUTION: A solubilizer for a nitrogen-containing compound contains tetraalkylammonium ions or tetraalkylphosphonium ions, and carboxylate ions.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to solubilizers for nitrogen-containing compounds. [Background technology]

[0002] Pharmaceuticals, quasi-drugs and cosmetics are formulated from a base and active ingredients, optionally mixed with additives to impart functionality.

[0003] Taking into consideration the stability and absorbability of the active ingredient, the active ingredient is utilized in the form of a neutral molecule or its salt. However, due to the low solubility of the active ingredient, there are issues such as difficulty in formulating the active ingredient for the intended administration route and inability to increase the concentration of the active ingredient in the formulation.

[0004] In recent years, ionic liquids have emerged as compounds exhibiting characteristic solubility, and their use as solubilizing agents for active ingredients such as pharmaceuticals has been reported. For example, Patent Document 1 describes that etodolac, which is a fat-soluble carboxylic acid and insoluble in water, can be solubilized in water by using an ionic liquid. Non-Patent Document 1 describes that some water-soluble proteins can be dissolved in an ionic liquid by using a sulfonic acid-based temperature-responsive ionic liquid. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2021 / 070893 [Non-patent literature]

[0006] [Non-Patent Document 1] AUST.J. CHEM. 2012, 65, 1548-1553. Summary of the Invention [Problem to be solved by the invention]

[0007] Patent Document 1 merely discloses that specific active ingredients such as etodolac can be solubilized. Non-Patent Document 1 writes that whether or not a protein dissolves in an ionic liquid depends on the protein, and merely discloses that the solubility of a specific protein can be improved.

[0008] Therefore, an object of the present invention is to provide a solubilizer or solvent for nitrogen-containing compounds which are widely used as active ingredients in medicines, quasi-drugs and cosmetics. [Means for solving the problem]

[0009] Means for Solving the Problems The present inventors have conducted extensive research to solve the above problems and have discovered the following inventions (1) to (11). (1) A solubilizing agent for nitrogen-containing compounds, which comprises a tetraalkylammonium ion or a tetraalkylphosphonium ion and a carboxylate ion. (2) The solubilizer according to (1), wherein the nitrogen-containing compound is a basic compound or a salt thereof, or a water-soluble compound. (3) The solubilizer according to (1) or (2), which satisfies the following formula 1: Concentration of nitrogen-containing compounds in the solubilizer layer / Concentration of nitrogen-containing compounds in the mixed solution before layer separation ≧ 5 Equation 1 (4) The solubilizer according to any one of (1) to (3), which satisfies the following formula 2: Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer ≧ 2 Equation 2 (5) A pharmaceutical composition comprising the solubilizer according to any one of (1) to (4) and a nitrogen-containing compound. (6) The pharmaceutical composition according to (5), wherein the solubilizing agent is an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, and the nitrogen-containing compound is a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, drugs for treating Parkinson's disease, antipsychotic drugs, drugs for treating dementia, drugs for treating attention deficit hyperactivity disorder, Janus kinase inhibitors, drugs for treating migraine, and phosphodiesterase 4 inhibitors. [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group. (7) The pharmaceutical composition according to (5) or (6), which is an external preparation. (8) A quasi-drug or cosmetic comprising the solubilizer according to any one of (1) to (4) and a nitrogen-containing compound. (9) The quasi-drug or cosmetic according to (8), wherein the solubilizer is an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, and the nitrogen-containing compound is selected from the group consisting of glutathione, pantothenic acid, tranexamic acid, L-cysteine, tryptophan, histidine, hydroxyproline, serine, glutamic acid, arginine, alanine, γ-aminobutyric acid, derivatives thereof, and pharmacologically acceptable salts thereof. [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group. (10) A method for dissolving a drug, comprising: a mixing step of mixing a nitrogen-containing compound, a tetraalkylammonium ion or a tetraalkylphosphonium ion, a solubilizing agent containing a carboxylate ion, and a liquid miscible with the solubilizing agent to prepare a mixed solution; and a separation step of subjecting the mixed solution to layer separation. (11) The method for dissolving a drug according to (10), wherein the concentration of the nitrogen-containing compound in the solubilizer layer after the separation step satisfies formula 1. Concentration of nitrogen-containing compounds in the solubilizer layer / Concentration of nitrogen-containing compounds in the mixed solution before layer separation ≧ 5 Equation 1 (12) The method for dissolving a drug according to (10), wherein the concentration of the nitrogen-containing compound in the solubilizer layer after the separation step satisfies formula 2. Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer ≧ 2 Equation 2 Effect of the Invention

[0010] According to the present invention, there is provided a solubilizer capable of dissolving a wide range of nitrogen-containing compounds used in pharmaceuticals, quasi-drugs, and cosmetics. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The solubilizer for nitrogen-containing compounds in the present invention is a solubilizer for nitrogen-containing compounds, characterized by containing a tetraalkylammonium ion or a tetraalkylphosphonium ion and a carboxylate ion. The solubilizer of the present invention may directly dissolve the nitrogen-containing compound, or may be used in combination with another solvent to dissolve the nitrogen-containing compound.

[0012] The solubilizer of the present invention contains a tetraalkylammonium ion or a tetraalkylphosphonium ion and a carboxylate ion. This combination of cation and anion facilitates the interaction of the solubilizer with the nitrogen-containing compound, and exhibits good solubility regardless of the physical properties of the nitrogen-containing compound. In addition, the solubilizer of the present invention has high affinity with other solvents used in pharmaceuticals, quasi-drugs, cosmetics, etc., and can solubilize the nitrogen-containing compound in other solvents, bases, etc.

[0013] The total carbon number of the four alkyl groups of the cation contained in the solubilizer of the present invention is preferably 13 to 35, more preferably 13 to 25. Examples of the tetraalkylammonium ion include tetrabutylammonium ion, tetrapentylammonium ion, tetrahexylammonium ion, tetraheptylammonium ion, tetraoctylammonium ion, and trioctylmethylammonium ion. Examples of the tetraalkylphosphonium ion include tetrabutylphosphonium ion, tetrapentylphosphonium ion, tetrahexylphosphonium ion, tetraoctylphosphonium ion, tributylhexylphosphonium ion, tributylheptylphosphonium ion, tributyloctylphosphonium ion, tributyldodecylphosphonium ion, tributyltridecylphosphonium ion, tributylpentadecylphosphonium ion, tributylhexadecylphosphonium ion, and trihexyltetradecylphosphonium ion. The four alkyl groups of the tetraalkylammonium ion or tetraalkylphosphonium ion may be the same or different. The alkyl group also includes an aromatic alkyl group such as a benzyl group.

[0014] The anion contained in the solubilizing agent of the present invention is a carboxylate ion (carboxylic acid ion), such as an aliphatic carboxylate ion (fatty acid ion), aromatic carboxylate ion (aromatic carboxylate ion), hydroxycarboxylate ion (hydroxycarboxylate ion), amino acid ion, etc., which may be a monovalent ion or a polyvalent carboxylate ion having a valence of divalent or more.

[0015] Examples of fatty acid ions include formate ion, acetate ion, propionate ion, butyrate ion, valerate ion, caproate ion, enanthate ion, caprylate ion, pelargonate ion, caprate ion, undecylate ion, laurate ion, tridecylate ion, myristate ion, pentadecylate ion, palmitate ion, margarate ion, stearate ion, nonadecylate ion, arachidate ion, henicosylate ion, behenate ion, tricosylate ion, lignocerate ion, cerotic acid ion, montanate ion, and melissic acid ion. and unsaturated fatty acid ions such as α-linolenate ion, stearidonic acid ion, eicosatetraenoate ion, eicosapentaenoate ion, docosapentaenoate ion, docosahexaenoate ion, linoleate ion, γ-linolenate ion, arachidonic acid ion, docosatetraenoate ion, docosapentaenoate ion, palmitoleate ion, vaccenic acid ion, paulic acid ion, oleate ion, elaidic acid ion, erucic acid ion, nervonic acid ion, sapienic acid ion, sorbic acid ion, and geranic acid ion.

[0016] Examples of hydroxycarboxylate ions include glycolate ion, lactate ion, tartronate ion, glycerate ion, hydroxybutyrate ion, malate ion, tartrate ion, citrate ion, isocitrate ion, citramalate ion, citronellate ion, leucate ion, mevalonate ion, pantoate ion, ricinoleate ion, quinate ion, and shikimate ion.

[0017] The anion contained in the solubilizing agent of the present invention is preferably an aromatic carboxylate ion, and more preferably an anion derived from salicylic acid or a salicylic acid derivative.

[0018] Examples of aromatic carboxylate ions include substituted or unsubstituted benzoate ions, for example, benzoate ions substituted with an alkyl group which may be substituted with a benzoate ion, a toluate ion, a trifluoromethylbenzoate ion, or the like; halogenated benzoate ions such as a fluorobenzoate ion, a chlorobenzoate ion, a bromobenzoate ion, or an iodobenzoate ion; acylated benzoate ions such as a formylbenzoate ion or an acetylbenzoate ion; alkoxylated benzoate ions or sulfobenzoate ions such as a hydroxybenzoate ion, an aminobenzoate ion, or a methoxybenzoate ion; and substituted or unsubstituted polycyclic aromatic carboxylate ions, for example, a naphthalenecarboxylate ion or an anthracenecarboxylate ion.

[0019] The position of the substituent on the aromatic carboxylate ion may be any position, and the number and type of the substituent are not particularly limited. When the substituent contains a hydroxyl group, an amino group, or the like, the hydroxyl group or the amino group may be further substituted with an acyl group, or the like.

[0020] Examples of the salicylic acid derivative in the anion derived from salicylic acid or a salicylic acid derivative include a compound having a substituent on the benzene ring of salicylic acid and a compound having a substituent on a phenolic hydroxyl group. In one embodiment, the anion contained in the solubilizer is, for example, an anion represented by the following general formula (I) or general formula (II). [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.

[0021] The solubilizing agent of the present invention is preferably an ionic liquid. An ionic liquid is defined as a salt having a melting point of 100° C. or less, in which either or both of the cation and the anion are organic (Science of Ionic Liquids - A Challenge to a New Generation of Liquids, p. 7).

[0022] When the solubilizer of the present invention contains an ionic liquid, it can be synthesized according to a general synthesis method of an ionic liquid. For example, when the ionic liquid is an ammonium salt, (1) a method (anion exchange method) in which an ammonium salt obtained by reacting an amine with an alkyl halide compound or the like is subjected to anion exchange using a metal salt and purified to obtain the desired ammonium salt, or (2) a method (neutralization method) in which an amine or ammonium hydroxide is directly reacted with an acid and neutralized to obtain the desired ammonium salt, can be mentioned. When the ionic liquid is a phosphonium salt, it can be synthesized by either the above-mentioned anion exchange method or neutralization method. In the case of the neutralization method, the desired phosphonium salt can be obtained by directly reacting a phosphonium hydroxide with an acid and neutralizing it.

[0023] In the synthesis of the ionic liquid used in the present invention, one type of cation and two or more types of anions, two or more types of cations and one type of anion, or two or more types of cations and two or more types of anions may be used. For example, an ionic liquid containing one type of cation and two types of anions can be obtained by mixing salicylic acid and 4-methoxysalicylic acid, which are anions, in any ratio so that the total amount of both is 1 mole per mole of tetrabutylphosphonium hydroxide, which is a cation.

[0024] The ionic liquid contained in the solubilizing agent of the present invention is preferably a temperature-responsive ionic liquid. The temperature-responsive ionic liquid refers to an ionic liquid that exhibits temperature responsiveness. By using the temperature-responsive ionic liquid, the nitrogen-containing compound can be dissolved in the ionic liquid at a higher concentration.

[0025] Here, temperature responsiveness refers to a property of changing shape and / or properties in response to a change in temperature (heat). Examples of the temperature responsiveness of an ionic liquid include volume changes such as expansion and contraction, and changes in hydrophobicity such as the lower critical solution temperature (hereinafter referred to as "LCST") and upper critical solution temperature (hereinafter referred to as "UCST").

[0026] Among the temperature-responsive ionic liquids, from the viewpoint of improving the solubility of the nitrogen-containing compound, a temperature-responsive ionic liquid having an LCST is preferred. From the viewpoint of preventing the decomposition of the nitrogen-containing compound during dissolution, the LCST is preferably 50° C. or less, more preferably 40° C. or less.

[0027] Examples of the temperature-responsive ionic liquid include temperature-responsive ionic liquids containing an anion represented by the above general formula (I) or general formula (II) and a tetraalkylammonium ion (e.g., tetrabutylammonium ion) or a tetraalkylphosphonium ion (e.g., tetraalkylphosphonium ion).

[0028] Examples of the temperature-responsive ionic liquid containing an anion represented by the above general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion include tetrabutylammonium salicylate, tetrabutylammonium 4-(trifluoromethyl)salicylate, tetrabutylphosphonium salicylate, tetrabutylphosphonium 4-(trifluoromethyl)salicylate, tetrabutylphosphonium acetylsalicylate, tetrabutylphosphonium 5-bromosalicylate, tetrabutylphosphonium 4-chlorosalicylate, tetrabutylphosphonium 5-chlorosalicylate, Examples of the tetrabutylphosphonium 5-iodosalicylate include tetrabutylphosphonium 3-methylsalicylate, tetrabutylphosphonium 4-methylsalicylate, tetrabutylphosphonium 5-sulfosalicylate, tetrabutylammonium 4-methoxysalicylate, tetrabutylammonium 4-fluorosalicylate, tetrabutylammonium 6-fluorosalicylate, tetrabutylphosphonium 4-methoxysalicylate, tetrabutylphosphonium 4-fluorosalicylate, tetrabutylphosphonium 6-fluorosalicylate, and tetrabutylphosphonium 3-phenylsalicylate.

[0029] The solubilizer of the present invention can be used by being blended in a pharmaceutical composition, a quasi-drug, or a cosmetic containing a nitrogen-containing compound. The nitrogen-containing compound is not particularly limited, and can be appropriately selected from known compounds.

[0030] Examples of the nitrogen-containing compound used in the pharmaceutical composition include aminosteroids such as rocuronium, nonsteroidal anti-inflammatory agents such as indomethacin, diclofenac, flufenamic acid, ketorolac, pranoprofen, or ester derivatives thereof, antiallergic agents such as tranilast, azelastine, ketotifen, ibudilast, oxatomide, or emedastine, antihistamines such as diphenhydramine, chlorpheniramine, promethazine, or tripelennamine, and central nervous system drugs such as chlorpromazine, nitrazepam, diazepam, phenobarbital, and reserpine. Nerve acting drugs, hormone drugs such as insulin, antihypertensive drugs such as clonidine or guanethidine sulfate, antiarrhythmic drugs such as propranolol hydrochloride, procainamide hydrochloride, ajmaline, pindolol or tulobuterol hydrochloride, coronary vasodilators such as nitroglycerin, isosorbide dinitrate, papaverine hydrochloride or nifedipine, local anesthetics such as lidocaine, benzocaine, procaine hydrochloride or tetracaine, analgesics such as morphine, codeine, tramadol, pregabalin, mirogabalin, acetanilide or aminopyrine, eperisone, tizanidine, skeletal muscle relaxants such as tolperisone, inaperisone, or pridinol mesylate; antifungal agents such as acetophenylamine, nitrofurazone, pentamycin, naphthiomate, miconazole, omoconazole, clotrimazole, butenafine hydrochloride, or bifonazole; anticancer agents such as 5-fluorouracil, actinomycin, bleomycin, or mitomycin; urinary disorder agents such as terodiline hydrochloride or oxybutynin hydrochloride; antiepileptic agents such as nitrazepam or meprobamate; Antipsychotics such as venlafaxine, blonanserin, aripiprazole, brexpiprazole, or mirtazapine; Dementia treatments such as memantine, donepezil, or rivastigmine; Attention Deficit Hyperactivity Disorder treatments such as methylphenidate, amphetamine, modafinil, atomoxetine, or guanfacine; Janus kinase inhibitors such as baricitinib, tofacitinib, ruxolitinib, peficitinib, filgotinib, delgocitinib, or abrocitinib; Sumatriptan, Zolmitriptan, Eletriptan,Examples of the drug include migraine treatment drugs such as rizatriptan or naratriptan, phosphodiesterase 4 inhibitors such as difamilast, roflumilast or apremilast, smoking cessation aids such as nicotine, vitamins, etc., and among these, it is preferable to use a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, Parkinson's disease treatment drugs, antipsychotic drugs, dementia treatment drugs, attention deficit hyperactivity treatment drugs, Janus kinase inhibitors, migraine treatment drugs, and phosphodiesterase 4 inhibitors, since these drugs can be suitably used as external preparations. In addition, these drugs may be their pharmacologically acceptable salts or solvates thereof.

[0031] Examples of nitrogen-containing compounds used in quasi-drugs and cosmetics include amino acids such as glutathione, pantothenic acid, tranexamic acid, L-cysteine, tryptophan, histidine, hydroxyproline, serine, glutamic acid, arginine, alanine, γ-aminobutyric acid, and their derivatives, kinetin, thiotaurine, urea, nicotinic acid, nicotinamide, minoxidil, D-glucosamine, N-acetyl-D-glucosamine, allantoin, L-carnitine, and biotin, among which glutathione, pantothenic acid, tranexamic acid, L-cysteine, tryptophan, histidine, hydroxyproline, serine, glutamic acid, arginine, alanine, γ-aminobutyric acid, and their derivatives, and their pharmacologically acceptable salts are preferred.In addition, these active ingredients may be their solvates.

[0032] Here, examples of pharmacologically acceptable salts include salts with inorganic acids or salts with organic acids. Examples of salts with inorganic acids include hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, or phosphate. Examples of salts with organic acids include oxalate, malonate, citrate, fumarate, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, ascorbate, glutarate, mandelate, phthalate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphorsulfonate, aspartate, glutamate, or cinnamate. Examples of solvates include hydrates.

[0033] The nitrogen-containing compound is preferably a basic compound or its salt, or a water-soluble compound. The basic compound is not particularly limited as long as it is a compound that exhibits basicity, such as amines. The reason why a basic compound or its salt, or a water-soluble compound is more preferable is that it is more likely to interact with the ionic liquid, and is more likely to exert an effect as a solubilizer.

[0034] As the pharmaceutical composition, a combination pharmaceutical composition in which the solubilizing agent is an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, and the nitrogen-containing compound is a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, drugs for treating Parkinson's disease, antipsychotic drugs, drugs for treating dementia, drugs for treating attention deficit hyperactivity disorders, Janus kinase inhibitors, drugs for treating migraine headaches, and phosphodiesterase 4 inhibitors is preferred. [ka] (In formula (II), R 1 R represents a hydrogen atom or an acyl group. 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.

[0035] The solubilizer of the present invention is preferably a solubilizer that satisfies the following formula 1. Concentration of nitrogen-containing compounds in the solubilizer layer / Concentration of nitrogen-containing compounds in the mixed solution before layer separation ≧ 5 Equation 1

[0036] By satisfying the above formula 1, the nitrogen-containing compound can be dissolved at a higher concentration in the solubilizer (B) layer. In addition, the higher the value obtained from formula 1, the higher the concentration of the nitrogen-containing compound dissolved in the solubilizer layer can be obtained. Therefore, the composition can be suitably used in pharmaceutical compositions, quasi-drugs, or cosmetics that contain active ingredients at high concentrations.

[0037] Moreover, it is preferable that the solubilizer of the present invention satisfies the following formula 2. Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer ≧ 2 Equation 2

[0038] By satisfying the above formula 2, the active ingredient can be dissolved at a high concentration in the solubilizer (B) layer after phase separation, and therefore can be suitably used in pharmaceutical compositions, quasi-drugs, or cosmetics that contain an active ingredient at a high concentration.

[0039] The nitrogen-containing compound concentrations in the above formulas 1 and 2 are calculated by measuring the nitrogen-containing compound concentrations before and after the separation step described below.

[0040] Since the pharmaceutical composition containing the solubilizing agent of the present invention can contain a high concentration of a nitrogen-containing compound drug, commonly known administration routes such as oral administration, nasal administration, transmucosal administration, intravenous administration, pulmonary administration, or parenteral administration such as transdermal administration can be used, and oral administration, transmucosal administration, or transdermal administration is preferred.

[0041] Dosage forms of the pharmaceutical composition containing the solubilizing agent of the present invention when administered orally include, for example, tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules and microcapsules), syrups, emulsions, or suspensions.

[0042] Preparations for oral administration can be prepared according to known manufacturing methods commonly used in the field of formulations, and can be produced by appropriately incorporating pharmacologically acceptable additives commonly used in the field of formulations, such as excipients, binders, lubricants, disintegrants, sweeteners, surfactants, suspending agents, or emulsifiers.

[0043] When the pharmaceutical composition containing the absorption control agent of the present invention is administered parenterally, examples of the dosage form include nasal preparations, eye drops, injections, infusions, drops, topical preparations, and suppositories. The pharmaceutical composition containing the absorption control agent of the present invention is preferably a topical preparation, which is a non-invasive administration method, because it can control the absorption of the active ingredient regardless of the skin condition.

[0044] The topical preparation may be in any conventionally used dosage form, such as an ointment, cream, gel, gel-like cream, lotion, spray, cataplasm, tape, or reservoir-type patch.

[0045] The preparation of the above-mentioned external preparation can be carried out according to a known manufacturing method generally used in the pharmaceutical field, and can be produced by appropriately adding pharmacologically acceptable additives generally used in the pharmaceutical field. Representative dosage forms, cataplasms and tapes, are described below, but are not limited thereto.

[0046] In preparing the cataplasm, for example, a water-soluble polymer or a polyhydric alcohol can be used as a pharmacologically acceptable additive.

[0047] Examples of water-soluble polymers include gelatin, casein, pullulan, dextran, sodium alginate, soluble starch, carboxystarch, dextrin, carboxymethylcellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, polyvinyl alcohol, polyethylene oxide, polyacrylic acid, polyacrylamide, sodium polyacrylate, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, methoxyethylene-maleic anhydride copolymer, isobutylene-maleic anhydride copolymer, N-vinylacetamide, and copolymers of N-vinylacetamide and acrylic acid or acrylate salts.

[0048] Examples of polyhydric alcohols include polyethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, isobutylene glycol, glycerin, diglycerin, and sorbitol.

[0049] In preparing the tape preparation, for example, an adhesive base or a tackifier can be used as a pharmacologically acceptable additive.

[0050] The adhesive base can be appropriately selected from known adhesives taking into consideration skin safety, medicinal ingredient release, adhesion to the skin, etc., and examples thereof include acrylic adhesives, rubber adhesives, and silicone adhesives.

[0051] Examples of the acrylic adhesive include homopolymers or copolymers of (meth)acrylic acid alkyl esters, and copolymers of the above-mentioned (meth)acrylic acid alkyl esters with other functional monomers.

[0052] Examples of rubber-based adhesives include natural rubber, synthetic isoprene rubber, polyisobutylene, polyvinyl ether, polyurethane, polyisoprene, polybutadiene, styrene-butadiene copolymer, styrene-isoprene copolymer, and styrene-isoprene-styrene block copolymer.

[0053] Examples of silicone-based adhesives include polyorganosiloxane and polydimethylsiloxane.

[0054] Examples of tackifiers include rosin-based rosin or hydrogenated, disproportionated, polymerized or esterified rosin derivatives, terpene resins such as α-pinene or β-pinene, terpene-phenol resins, aliphatic, aromatic, alicyclic or copolymer petroleum resins, alkyl-phenyl resins, and xylene resins.

[0055] Quasi-drugs and cosmetics containing the solubilizer of the present invention can be produced according to known methods. In addition to the active ingredient and the absorption control agent of the present invention, powder components, oily components, UV absorbers, various aqueous solvents, sequestering agents, monosaccharides, oligosaccharides, amino acids, organic amines, polymer emulsions, alcohols, pH adjusters, dispersants, antioxidants, fragrances, preservatives, stabilizers, etc. can be appropriately blended as necessary.

[0056] Quasi-drugs and cosmetics containing the solubilizer of the present invention can be in any conventionally used dosage form, such as ointments, creams, gels, gel-like creams, lotions, sprays, patches, tapes, etc. Specific examples of such products include skin lotions, milky lotions, beauty essences, and skin care creams.

[0057] As a quasi-drug or cosmetic product, the solubilizer is preferably an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, and the nitrogen-containing compound is preferably a combination selected from the group consisting of glutathione, pantothenic acid, tranexamic acid, L-cysteine, tryptophan, histidine, hydroxyproline, serine, glutamic acid, arginine, alanine, γ-aminobutyric acid, and derivatives thereof. [ka] (In formula (II), R 1 represents a hydrogen atom or an acyl group, R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.

[0058] The present invention provides a method for dissolving a nitrogen-containing compound, specifically, the method for dissolving a drug, comprising a mixing step of mixing a nitrogen-containing compound (A), a solubilizing agent (B) containing tetraalkylammonium ions or tetraalkylphosphonium ions and carboxylate ions, and a liquid (C) miscible with the solubilizing agent to prepare a mixed solution, and a separation step of separating the mixed solution into layers.

[0059] The solution obtained in the mixing step of mixing the nitrogen-containing compound (A), the solubilizing agent (B) containing tetraalkylammonium ions or tetraalkylphosphonium ions and carboxylate ions, and the liquid (C) miscible with the solubilizing agent is preferably a homogeneous solution, but may also be a dispersion in which the nitrogen-containing compound is dispersed as long as it is not separated into layers.

[0060] The method for layer separation in the separation step is not particularly limited as long as it is a method for layer-separating a solution obtained by mixing the nitrogen-containing compound (A), the solubilizing agent (B) containing tetraalkylammonium ions or tetraalkylphosphonium ions and carboxylate ions, and the liquid (C) that is miscible with the solubilizing agent. From the viewpoint of ease of operation, a method using heating or cooling is preferred.

[0061] The solubilizer (B) used in the method for dissolving a nitrogen-containing compound of the present invention is preferably a temperature-responsive ionic liquid. By using a temperature-responsive ionic liquid, layer separation can be easily performed by heating or cooling, and the nitrogen-containing compound can be dissolved at a high concentration in the solubilizer (B) layer.

[0062] The method for dissolving the nitrogen-containing compound of the present invention is preferably a dissolving method in which the concentration of the nitrogen-containing compound in the solubilizer (B) layer after layer separation satisfies the following formula 1. Concentration of nitrogen-containing compounds in the solubilizer layer / Concentration of nitrogen-containing compounds in the mixed solution before layer separation ≧ 5 Equation 1

[0063] In the above formula 1, the nitrogen-containing compound concentration is measured by measuring the nitrogen-containing compound concentration in the separated solubilizer (B) layer after the separation step and in the mixed solution before the separation step. Specifically, a nitrogen-containing compound (A), a solubilizer (B) containing tetraalkylammonium ions or tetraalkylphosphonium ions and carboxylate ions, and a liquid (C) miscible with the solubilizer are mixed to prepare a mixed solution, and then the mixed solution is separated into layers. The nitrogen-containing compound concentration is measured in the separated solubilizer (B) layer and in the mixed solution before layer separation. As a method for measuring the nitrogen-containing compound concentration, known methods such as HPLC-UV, LC / MS, and LC / MS / MS can be used. In addition, in the case of a fluorescent substance, a fluorescent plate reader or a fluorescent spectrophotometer can be used.

[0064] By satisfying formula 1, the nitrogen-containing compound can be dissolved at a higher concentration in the solubilizer (B) layer. Moreover, the higher the value obtained from formula 1, the higher the concentration of the nitrogen-containing compound dissolved in the solubilizer layer can be obtained.

[0065] The method for dissolving the nitrogen-containing compound of the present invention is preferably a dissolving method in which the concentration of the nitrogen-containing compound in the solubilizer (B) layer after layer separation satisfies the following formula 2. Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer ≧ 2 Equation 2

[0066] By satisfying the above formula 2, the solubilizer (B) can be dissolved at a high concentration in the layer after layer separation.

[0067] In the above formula 2, the nitrogen-containing compound concentration is measured by measuring the nitrogen-containing compound concentration in each of the separated solubilizer (B) layer and liquid (C) layer after the separation step. Specifically, a nitrogen-containing compound (A), a solubilizer (B) containing tetraalkylammonium ions or tetraalkylphosphonium ions and carboxylate ions, and a liquid (C) miscible with the solubilizer are mixed to prepare a mixed solution, and then the mixed solution is separated into layers. The nitrogen-containing compound concentration is measured in each of the separated solubilizer (B) layer and liquid (C) layer. As a method for measuring the nitrogen-containing compound concentration, known methods such as HPLC-UV, LC / MS, and LC / MS / MS can be used. In addition, in the case of a fluorescent substance, a fluorescent plate reader or a fluorescent spectrophotometer can be used.

[0068] By using the method for dissolving a nitrogen-containing compound that satisfies the above formula 1 or 2, a solubilizer (B) layer in which the nitrogen-containing compound is dissolved at a high concentration can be obtained. After the solubilizer (B) layer in which the nitrogen-containing compound is dissolved at a high concentration is taken out, a pharmaceutical composition, a quasi-drug, or a cosmetic in which the nitrogen-containing compound is dissolved at a high concentration can be produced by blending other ingredients therewith.

[0069] In the dissolution method, after the separation step, a removal step of, for example, removing the liquid (C) miscible with the solubilizer of the present invention under reduced pressure can be performed to obtain a solubilizer (B) layer in which the nitrogen-containing compound is dissolved at a high concentration. By adding other ingredients to the obtained mixture of the nitrogen-containing compound and solubilizer (B), a pharmaceutical composition, quasi-drug, or cosmetic in which the nitrogen-containing compound is dissolved at a high concentration can be produced.

[0070] The nitrogen-containing compound (A) is preferably a basic compound, its salt, or a water-soluble compound. The basic compound is not particularly limited as long as it is a compound that exhibits basicity, such as amines. The reason why a basic compound, its salt, or a water-soluble compound is more preferable is that it is more likely to interact with the solubilizer of the present invention, and is more likely to exert its effect as a solubilizer.

[0071] The liquid (C) that is miscible with the solubilizer is not particularly limited as long as it is a liquid that is miscible with the solubilizer, and may be, for example, water, alcohols such as methanol, ethanol, propanol, butanol, or propanediol, or a commonly available organic solvent. EXAMPLES

[0072] The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto. In addition, for compounds used in the synthesis of the compounds in the examples and comparative examples for which no synthesis method is described, commercially available compounds were used. Unless otherwise specified, commercially available reagents were used in the reactions without purification. First, the measurement and test methods are shown below.

[0073] (Synthesis Example 1) Synthesis of solubilizer: As the cationic component, 6.91 g (10 mmol) of a 40% by mass aqueous solution of tetrabutylphosphonium hydroxide and 1.38 g (10 mmol) of salicylic acid were weighed as the anionic component and placed in a glass vial. The mixture was stirred at room temperature for 2 hours, and the reaction was terminated when it was confirmed that the salicylic acid had completely dissolved, thereby quantitatively obtaining a mixed solution of tetrabutylphosphonium salicylate and water (hereinafter referred to as "Sample 1"). Sample 1 was diluted and used for the dissolution test of nitrogen-containing compounds.

[0074] (Example 1) Dissolution test in solubilizer using nitrogen-containing compound In a glass screw bottle, a solution was prepared by dissolving nitrogen-containing compounds in a 10% aqueous solution of solubilizer so that the nitrogen-containing compound concentration was 1 mg / mL. 1.4 mL of the solution was transferred to a 1.5 mL tube and left to stand in a 40°C incubator for 3 hours, and a separation process was carried out to separate the solution into an ionic liquid layer and an aqueous layer. The solubilizer (B) layer and the aqueous liquid (C) layer were collected with a syringe, and the concentration of the nitrogen-containing compounds dissolved in each layer was measured using LC / MS / MS.

[0075] The aqueous solution of the solubilizer used was prepared by diluting Sample 1 to the above concentration.

[0076] (LC / MS / MS analysis conditions) Liquid chromatograph (LC): Prominence UFLC (Shimadzu Corporation) Mass spectrometer (MS / MS): QTRAP (registered trademark) 3200 (manufactured by Sciex) or LC: Exion LC (Sciex) MS / MS: TripleQuad (registered trademark) 7500 (manufactured by Sciex) Column: CAPCELL PAK C18 MGIII, 5 μm, 2.0 mm ID × 50 mm (Osaka Soda Co., Ltd.) Mobile phase: A: 0.1% by weight formic acid aqueous solution B: 0.1% by weight formic acid-containing acetonitrile Gradient conditions: A:B = 95:5 → 10:90 Column temperature: 40℃ Flow rate: 0.5mL / min Measurement time: 5 minutes Sample injection volume: 10 μL (for Prominence UFLC) 1μL (for Exion LC)

[0077] (Comparative Example 1) Dissolution test in a solubilizing agent using a compound not containing nitrogen The test was carried out in the same manner as in Example 1, except that sodium fluorescein was used as the nitrogen-free compound and the compound concentration was 0.5 mg / mL. The concentration of sodium fluorescein was measured using a fluorescent plate reader.

[0078] [Table 1]

[0079] As for the nitrogen-containing compounds sumatriptan succinate, memantine hydrochloride, venlafaxine hydrochloride, atomoxetine hydrochloride and guanfacine hydrochloride, the concentrations of the nitrogen-containing compounds in the solubilizer (B) layer were significantly higher by 48.1 to 275.8 times than the concentrations in the liquid (C) layer, and the concentrations in the solubilizer (B) layer were also higher by 8.8 to 9.9 times than the concentrations in the mixed solution before separation, confirming that the solubilizer of the present invention can be used as an excellent solubilizer for nitrogen-containing compounds. On the other hand, in the case of sodium fluorescein, a compound not containing nitrogen, the concentration in the solubilizer (B) layer was 1.2 times that of the liquid (C) layer, and the concentration in the solubilizer (B) layer was also almost the same as the concentration in the mixed solution before separation, at 1.2 times. [Industrial Applicability]

[0080] The solubilizer of the present invention can dissolve a nitrogen-containing compound used as an active ingredient at a high concentration, and can therefore be used in medicines such as external preparations, quasi-drugs, cosmetics, and the like.

Claims

1. A solubilizing agent for nitrogen-containing compounds comprising a tetraalkylammonium ion or a tetraalkylphosphonium ion and a carboxylate ion.

2. The solubilizing agent according to claim 1 , wherein the nitrogen-containing compound is a basic compound or a salt thereof, or a water-soluble compound.

3. The solubilizer according to claim 1 or 2, which satisfies the following formula 1: Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in mixed solution before layer separation≧5 Equation 1

4. The solubilizer according to any one of claims 1 to 3, which satisfies the following formula 2: Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer≧2 Equation 2

5. A pharmaceutical composition comprising the solubilizer according to any one of claims 1 to 4 and a nitrogen-containing compound.

6. The solubilizing agent is an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, The pharmaceutical composition according to claim 5, wherein the nitrogen-containing compound is a basic drug selected from the group consisting of skeletal muscle relaxants, antiepileptic drugs, drugs for treating Parkinson's disease, antipsychotic drugs, drugs for treating dementia, drugs for treating attention deficit hyperactivity disorders, Janus kinase inhibitors, drugs for treating migraine headaches, and phosphodiesterase 4 inhibitors. 【Chemistry 1】 (In formula (II), R 1 represents a hydrogen atom or an acyl group; R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.

7. The pharmaceutical composition according to claim 5 or 6, which is an external preparation.

8. A quasi-drug or cosmetic comprising the solubilizer according to any one of claims 1 to 4 and a nitrogen-containing compound.

9. The solubilizing agent is an ionic liquid containing an anion represented by the following general formula (I) or general formula (II) and a tetraalkylammonium ion or a tetraalkylphosphonium ion, The quasi-drug or cosmetic according to claim 8, wherein the nitrogen-containing compound is selected from the group consisting of glutathione, pantothenic acid, tranexamic acid, L-cysteine, tryptophan, histidine, hydroxyproline, serine, glutamic acid, arginine, alanine, γ-aminobutyric acid, derivatives thereof, and pharmacologically acceptable salts thereof. 【Chemistry 2】 (In formula (II), R 1 represents a hydrogen atom or an acyl group; R 2 represents an alkyl group which may be substituted with a halogen atom, a halogen atom, a sulfo group, an aryl group, or an alkoxy group.

10. a mixing step of mixing a nitrogen-containing compound, a tetraalkylammonium ion or a tetraalkylphosphonium ion, a solubilizing agent containing a carboxylate ion, and a liquid miscible with the solubilizing agent to prepare a mixed solution; A method for dissolving a drug, comprising a step of separating the mixed solution into layers.

11. The method for dissolving a drug according to claim 10, wherein the concentration of the nitrogen-containing compound in the solubilizer layer after the separation step satisfies formula 1. Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in mixed solution before layer separation≧5 Equation 1

12. The method for dissolving a drug according to claim 10, wherein the nitrogen-containing compound concentration in the solubilizer layer after the separation step satisfies formula 2. Concentration of nitrogen-containing compound in solubilizer layer / Concentration of nitrogen-containing compound in liquid layer≧2 Equation 2

Citation Information

Patent Citations

  • Pharmaceutical composition including temperature-responsive ionic liquid

    WO2021070893A1